
CRISPR knockout cell lines are engineered through targeted genome editing to eliminate gene function, supporting studies of cellular biology, disease mechanisms, and drug discovery.
JIMT-1 is a human breast cancer cell line established from the pleural effusion of a 62-year-old female patient with grade 3 invasive ductal breast carcinoma (T2N1M0) after postoperative radiation therapy. The cells carry amplification of the HER2 oncogene and have been reported to be insensitive to HER2-targeted therapies, including trastuzumab. JIMT-1 is widely used as a model for studying HER2-positive breast cancer biology, mechanisms of therapeutic resistance, and evaluation of novel anti-HER2 treatments.
Each knockout cell line is validated by STR authentication, sterility testing (bacteria/fungi), and mycoplasma screening. Genotype is confirmed by two rounds of PCR and Sanger sequencing. Only clones that pass all QC criteria are released, ensuring reliable identity and performance for downstream applications.

Cas9 cell lines in our cell bank can stably express Cas9 protein. Each Cas9 Stable Cell Line is easy to use and enables gene knockout simply by transfecting gRNA, while transfection of gRNA and donor DNA results in gene knock-in or point mutations
These Cas9 stable cell lines have been used to construct the KO cell lines for various genes, gene KO efficiency 5-10 times improved.
Selected cells, low passages, good cell condition, high activity, applicable for all kinds of gene-editing experiments.
Targeted knockout region: EExon 3
Reference Transcript: NM_014911
Frameshift Mutation Strategy
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use






Simply fill out the form below to leave your inquiry
— we will respond within 24 Hours
* Name
* Institution
* Products & Services of Interest
If email is not available, how else can we reach you?
How did you hear about us?